Production (Stage)
BioRestorative Therapies, Inc.
BRTX
$1.66
$0.063.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.00K | 43.30K | 233.60K | 89.10K | 35.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.00K | 43.30K | 233.60K | 89.10K | 35.00K |
| Cost of Revenue | 2.90K | 3.30K | 18.20K | 6.50K | -- |
| Gross Profit | 22.10K | 40.00K | 215.40K | 82.60K | 35.00K |
| SG&A Expenses | 3.12M | 1.07M | 1.18M | 1.26M | 3.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.83M | 2.73M | 2.52M | 2.56M | 4.14M |
| Operating Income | -4.81M | -2.69M | -2.29M | -2.47M | -4.11M |
| Income Before Tax | -5.34M | -1.64M | -1.09M | -4.03M | -2.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.34M | -1.64M | -1.09M | -4.03M | -2.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.34M | -1.64M | -1.09M | -4.03M | -2.22M |
| EBIT | -4.81M | -2.69M | -2.29M | -2.47M | -4.11M |
| EBITDA | -4.76M | -2.64M | -2.24M | -2.42M | -4.07M |
| EPS Basic | -0.64 | -0.20 | -0.13 | -0.50 | -0.33 |
| Normalized Basic EPS | -0.40 | 0.01 | -0.08 | -0.31 | -0.21 |
| EPS Diluted | -0.64 | -0.20 | -0.13 | -0.50 | -0.33 |
| Normalized Diluted EPS | -0.40 | 0.01 | -0.08 | -0.31 | -0.21 |
| Average Basic Shares Outstanding | 8.36M | 8.13M | 8.12M | 8.12M | 6.67M |
| Average Diluted Shares Outstanding | 8.36M | 8.13M | 8.12M | 8.12M | 6.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |